Corteva (CTVA)
NYSEMaterialsAgricultural InputsSnapshot 2026-09-04
NYSEMaterialsAgricultural InputsSnapshot 2026-09-04
Research Workspace
Put CTVA beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Materials: fringe margins under pressure (0q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Recent financial performance freshly dropped to the bottom half of its industry.
View ThesisRevenue is growing steadily — about 4% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, the balance sheet.
View ManagementExpectations look high — the market is pricing in about 25% growth a year, above the roughly 4% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskCorteva's growth in the Seed segment through technology and pricing must continue to justify the price. Revenue growth has been weak, with a recent earnings beat of 2.3 per share. The stock trades at 23× P/E, above the 18× peer median, indicating that the market prices in more growth than forecast. Recent financial performance dropped to the bottom half of its industry, marking a significant risk. Peer multiples imply a price about 25% below where it trades, suggesting it looks expensive on this basis. This read is provisional.
Trailing returns as of 2026-09-04. CTVA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 21 analysts currently covering CTVA (as of Sep 2026).
Based on 7 Wall Street analysts offering 12-month price targets for CTVA in the last 4 months.
Continue this research
Compare CTVA with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CTVA Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Fertilizers & Agricultural Chemicals — fair value, gap to price, and forward P/E.
Compare the value case
Put CTVA next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Drive growth in Seed segment through technology and pricing
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $87.86
The last 12 months of price, then the range of analyst 12-month targets from today’s $87.86.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
High demand for tech seeds supports growth in Seed segment.
Advances: Complete planned separation by 2026-Q4
Amendment supports planned separation by 2026-Q4.

Advances: Focus on Crop Protection revenue growth
Joint development enhances Crop Protection revenue growth potential.

Advances: Enhance Seed segment performance
Enhances Seed segment performance through new product integration.
Advances: Complete planned separation by 2026-Q4
Board announcement supports planned separation by 2026-Q4.
Advances: Complete planned separation by 2026-Q4
Naming board aids in executing crop protection spinoff.
Partnership enhances Crop Protection Revenue Growth potential.
Threatens: Complete planned separation by 2026-Q4
Ceasing production may delay separation plans.